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Background: We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1
receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with
refractory advanced non-small-cell lung cancer (NSCLC).The phase I trial determined the recommended dose and
safety of erlotinib plus dalotuzumab at 5 mg/kg or 10 mg/kg weekly in 20 patients. The phase II trial compared
outcomes to erlotinib alone and erlotinib plus dalotuzumab at the mg/kg established in the phase I trial.
Results: Erlotinib at 150 mg plus dalotuzumab at 10 mg/kg was safe. The phase II trial included 37 patients in the
erlotinib arm and 38 patients in the erlotinib plus dalotuzumab arm. Progression-free survival was 1.6 versus 2.5 months,
overall survival was 10.2 and 6.6 months, and the objective response rate was 7.9% and 2.7%, respectively, with no
significant differences between the two arms. Grade 3-5 adverse events occurred in 11 (28.9%) versus 13 (35.1%)
patients, respectively. The most frequent adverse events were asthenia (36.8% vs. 37.8%), dehydration (5.3% vs. 2.7%),
diarrhea (71% vs. 81.1%), hyperglycemia (13.1% vs.18.9%), and skin-related toxicities (92.1% vs. 86.4%).
Conclusion: The addition of dalotuzumab to erlotinib did not improve efficacy outcome in patients with refractory
advanced NSCLC.
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Phase I/II trialIntroduction
Insulin-like growth factor 1 receptor (IGF1R) is overex-
pressed in a wide variety of human malignances, including
non-small-cell lung cancer (NSCLC) [1-3]. Additionally,
high co-expression of IGF1R and epidermal growth factor
receptor (EGFR) has been correlated with shorter disease-
free survival in NSCLC patients [4]. Cross-talk between
the EGFR and IGF1R pathways contributes to trans-
formation, growth, and tumor responsiveness to EGFR
inhibitors [5].* Correspondence: mmoran@iconcologia.net
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unless otherwise stated.Dalotuzumab, formerly MK-0646, is a humanized IgG1
anti-IGF1R monoclonal antibody (MoAb) that selectively
binds to IGF1R without binding to insulin receptor (IR).
By binding to the extracellular domain of the receptor,
dalotuzumab blocks ligand binding and inhibits receptor
autophosphorylation by up to 90%, leading to a block in
IGF1- and IGF2-mediated cell proliferation in vitro and
down-regulation of cell surface receptors by 75% to 90%.
According to previous phase I trials, dalotuzumab reached
a biologically optimal concentration when a dose of
10 mg/kg/week was administered and plasma IGF1R
levels increased after dalotuzumab administration inde-
pendently of the administered dose [6,7].
We hypothesized that dual inhibition of the EGFR
and IGF1R pathways could prove beneficial in NSCLCLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the combination of erlotinib and dalotuzumab in unse-
lected, advanced NSCLC patients who were refractory to
previous chemotherapy.
Methods
Patient selection
This study was designed as a phase I/II trial. Patients were
recruited from five centers for the phase I trial and 20 cen-
ters for the phase II trial from Europe, the United States
and Canada (Figure 1). Patients were eligible for inclusion if
they were 18 years or older and had histologically docu-
mented advanced NSCLC refractory to previous therapy (at
least one and no more than two previous chemotherapy
regimens) The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice Guide-
lines. The protocol was approved by local ethics commit-
tees at each participating center, and all patients gave their
signed informed consent for participation in the study.Figure 1 CONSORT diagram showing patient disposition through theStudy design and treatment
The phase I trial consisted of a safety and tolerability
run-in study testing dalotuzumab at two dose levels that
had previously been demonstrated as safe with an adequate
pharmacodymamic profile (5 and 10 mg/kg). Erlotinib
was administered as a daily oral dose of 150 mg and
dalotuzumab as a 60-minute weekly intravenous infusion.
Dalotuzumab was administered following a “3 + 6” escal-
ation scheme design, with an anticipated intermediate
dose level of 7.5 mg/kg in the event of intolerable toxicity
at the higher dose level.
In the phase II trial, patients were randomized to the
control or experimental arm. Patients in the control arm
received erlotinib alone, and those in the experimental
arm received erlotinib plus dalotuzumab at the dose
level determined by the phase I trial. Both dalotuzumab
and erlotinib were provided by the sponsor of the trial,
Merck Sharp & Dohme Corp., a subsidiary of Merck &
Co, Inc., Whitehouse Station, NJ, USA.phase I and phase II trials.
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For the phase I trial, the primary objective was to deter-
mine the safety and tolerability of erlotinib in combination
with dalotuzumab in patients with advanced NSCLC. For
clinical assessment of toxicity, patients were evaluated
weekly and adverse events were graded according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events version 3.0 [8]. For the purpose of
determination of protocol dose escalation in phase I, dose
limiting toxicity (DLT) was defined based on the events
occurring within the first 4 weeks of therapy. For patient
management, dose modification would occur in the event
of DLT occurring during any cycle of therapy. Hema-
tologic DLT were defined as grade 4 neutropenia lasting
for ≥7 days, grade 3 or 4 neutropenia with fever >38.5°
and/or infection requiring antibiotics or anti-fungal
therapy and grade 4 thrombocytopenia (≤25.0 × 109/L).
Non-hematologic DLT were defined as any ≥ grade 3 non-
hematologic toxicity, with the specific exception of grade
3 skin toxicity, nausea and/or vomiting, diarrhea, dehydra-
tion or hyperglycemia that in the opinion of the investiga-
tor occurred in the setting of inadequate compliance with
supportive care measures and lasted less than 48 hours.
For the phase II trial, the primary efficacy endpoint
was progression-free survival (PFS); secondary endpoints
were response rate, overall survival (OS) and safety and
tolerability. PFS was defined as the time from ran-
domization until either radiographic evidence of disease
progression or death due to any cause, whichever occurred
first. OS was defined as the time from randomization to
death due to any cause. Response was graded according
to the Response Evaluation Criteria in Solid Tumors
(RECIST) 1.0 guidelines [9]. Radiographic evaluation was
performed every six weeks during the first 48 weeks and
every three months thereafter. For sample size calculation
and PFS estimation, 49 PFS events in both control and
experimental arms were planned and 68 patients with a
projected follow-up of 5 months were needed. The
present study had 80% power to detect an improvement
in PFS defined as a 45.5% reduction in the hazard ratio in
the combination arm. A 45.5% reduction in hazard rate
corresponds to 1.84 months in improvement in median
PFS compared to the erlotinib arm.
Results
Patients
From 19 Mar 2008 to 5 Jun 2009, 23 patients were
enrolled in the phase I trial. Four patients were included
in the first dose cohort (erlotinib 150 mg daily orally plus
dalotuzumab 5 mg/kg/week intravenously) and sixteen
in the second dose cohort (erlotinib 150 mg daily orally
plus dalotuzumab 10 mg/kg/week intravenously). From
11 Aug 2010 to 24 Mar 2011, 83 patients were enrolled
in the phase II trial. Eight were excluded from the analysisleaving 75 patients, 38 in the control arm and 37 in the
experimental arm. Clinical characteristics for patients in
both phases are summarized in Table 1. Although the
phase I trial was based in a “3 + 6” escalation scheme de-
sign, five patients were removed due to progressive disease
before the first four weeks of dosing that were needed to
monitor for DLTs. Three additional patients were included
by decision of the study sponsor to ensure that the final
sample included at least 9 fully evaluable patients.
Safety
In the phase I trial, the most common toxicities were those
related to erlotinib. Thirteen patients (65%) developed
diarrhea (two grade 3), and 50% suffered ≤ grade 2 rash or
acneiform dermatitis (Table 2). One patient experienced
grade 3 erythema. Dalotuzumab-related toxicities include
hyperglycemia in 8 patients (five grade 3). Four of these 8
patients had a previous diagnosis of diabetes mellitus
and were receiving treatment for diabetes before initiating
the study.
Erlotinib-related toxicities in the phase II trial included
skin toxicity (reported as rash or acneiform dermatitis) in
35 (92.1%) patients in the control arm and 32 (86.4%) pa-
tients in the experimental arm, asthenia in 14 (36.8%) and
14 (37.8%) patients, dehydration in 2 (5.3%) and 1 (2.7%),
and diarrhea in 27 (71%) and 30 (81.1%), respectively.
Hyperglycemia was seen in 5 (13.1%) patients in the control
arm and 7 (18.9%) in the experimental arm. Grade 3-5
hyperglycemia was observed in 4 (10.52%) and 4 (10.81%)
patients, respectively. Although grade 3 to 5 adverse events
are reported together, no grade 5 hyperglycemia was
observed. One death, probably related to interstitial lung
disease, was reported in the erlotinib arm (2.63%) (Table 2).
Efficacy
No significant differences were observed in PFS or OS
between the two treatment arms in the phase II trial.
PFS was 1.6 months in the control arm and 2.5 months
in the experimental arm (hazard ratio [HR]: 0.86, 95%
CI: 0.47-1.57; p =0.268). OS was 10.2 months in the
control arm and 6.6 months in the experimental arm
(HR: 1.80, 95% CI: 0.87-3.72; p =0.946].
No significant difference in overall response rate was
observed between the two arms. Three partial responses
(PR) were observed in the control arm (7.9%) and one
(2.8%) in the experimental arm, and there were no
complete responses in either arm. All four patients with
PR had adenocarcinomas. Twenty-one (55.3%) patients
in the control arm and 21 (56.7%) in the experimental
arm had stable disease (SD) as best response. Stable
disease between 3 and 12 months was attained by seven
patients in each arm (18.4% and 18.9%, respectively), and
SD lasted longer than 12 months in three and two patients,
respectively (Table 3).
Table 1 Baseline patient characteristics
Phase I Phase II
Dalotuzumab 5 mg/kg
plus erlotinib cohort 1
Dalotuzumab 10 mg/kg
plus erlotinib cohort 2
Erlotinib Dalotuzumab
plus erlotinib
n =4 n =16 n =38 n =37
Gender Gender
Male 4 (100%) 14 (87.6%) Male 28 (73.7%) 27 (73%)
Female 0 (0%) 2 (12.5%) Female 10 (26.3%) 10 (27%)
Age (years) Age (years)
Mean 53.8 61.9 Mean 58.5 61.9
SD 3.9 7.7 SD 10.4 7.83
Median 53.5 62.0 Median 59.0 62.0
Range 50 to 58 50 to 72 Range 36 to 80 45 to 77
Race Race
Caucasian 4 (100%) 16 (100%) Caucasian 36 (94.7%) 37 (100%)
Asian 0 (0%) 0 (0%) Asian 2 (5.3%) 0 (0%)
ECOG performance status ECOG performance status
0 4 (100%) 5 (31.4%) 0 13 (34.2%) 11 (29.7%)
1 0 (0%) 11 (68.8%) 1 24 (63.2%) 24 (64.9%)
2 0 (0%) 0 (0%) 2 1 (2.6%) 2 (5.5%)
Stage Stage
IIIB 1 (25%) 2 (12.5%) IIIB 9 (23.7%) 4 (10.8%)
IV 3 (75%) 14 (87.5%) IV 29 (76.3%) 33 (89.2%)
Smoking history Smoking history
Current smoker 1 (25%) 5 (31.1%) Current smoker 7 (18.4%) 12 (32.4%)
Former smoker 3 (75%) 7 (43.8%) Former smoker 20 (52.6%) 21 (56.8%)
Never smoker 0 (0%) 4 (25%) Never smoker 11 (28.9%) 4 (10.8%)
Previous therapies Previous treatments
Mean 1.5 1.5 First-line only 20 (52.6%) 27 (72.9%)
Median 1 1.5 First- and second-line 18 (47.4%) 10 (27.02%)
Range 1 to 3 1 to 3 Prior platinum-containing regimen 38 (100%) 35 (94.6%)
Previous diagnosis
of diabetes
0 (0%) 4 (25%) Previous diagnosis
of diabetes
4 (10.4%) 2 (5.4%)
Previous treatments
for diabetes
0 (0%) 4 (25%) Previous treatments
for diabetes
4 (10.4%) 2 (5.4%)
Glimepiridine 1 (2.6%) 0 (0%)
Glyburide 0 (0%) 1 (6.2%) Glyburide 1 (2.6%) 0 (0%)
Insulin 0 (0%) 1 (6.2%) Insulin 0 (0%) 1 (2.7%)
Metformin 0 (0%) 1 (6.2%) Metformin 1 (2.6%) 1 (2.7%)
Rapaglinide 0 (0%) 1 (6.2%) Pioglitazone 1 (2.6%) 0 (0%)
Histology Histology
Adenocarcinoma 1 (25%) 5 (31.3%) Adenocarcinoma 15 (39.5%) 14 (37.8%)
Squamous cell carcinoma 3 (75%) 4 (25%) Squamous cell carcinoma 6 (15.8%) 11 (29.7%)
Large cell carcinoma 0 (0%) 1 (6.3%) Large cell carcinoma 0 (0%) 1 (2.7%)
Not otherwise specified 0 (0%) 6 (37.5%) Not otherwise specified 17 (44.7%) 11 (29.7%)
ECOG = Eastern Cooperative Oncology Group.
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Table 2 Summary of adverse events
Event
Phase I Phase II
Dalotuzumab
5mg/kg plus erlotinib
Dalotuzumab
10 mg/kg plus erlotinib Erlotinib
Dalotuzumab
10 mg/kg plus erlotinib
N = 4 N = 16 N = 38 N = 37
Diarrhea
AE 1 (25%) 12 (75%) 27 (71%) 30 (81.1%)
SAE 0 2 (12.6%) 0 0
Drug-related AE 1 (25%) 10 (62.5%) 18 (47.3%) 16 (43.2%)
g3-5 0 2 (12.5%) 1 (2.6%) 3 (8.1%)
Nausea
AE 0 5 (31.2%) 17 (44.7%) 17 (45.9%)
SAE 0 0 0 0
Drug-related AE 0 3 (18.7%) 4 (10.5%) 6 (16.2%)
g3-5 0 0 0 0
Stomatitis
AE 2 (50%) 5 (31.2%) 3 (7.9%) 4 (10.8%)
SAE 0 0 0 0
Drug-related AE 1 (25%) 3 (18.5%) 2 (5.3%) 3 (8.1%)
g3-5 0 0 0 0
Asthenia
AE 1 (25%) 10 (62.5%) 14 (36.8%) 14 (37.8%)
SAE 0 0 1 (2.6%) 0
Drug-related AE 0 1 (6.2%) 7 (18.4%) 3 (8.1%)
g3-5 0 1 (6.2%) 2 (5.3%) 2 (5.4%)
Hepatobiliary disorders
AE 0 0 4 (10.5%) 4 (10.8%)
SAE 0 0 0 2 (5.4%)
Drug-related AE 0 0 1 (2.6%) 0
g3-5 0 0 0 2 (5.4%)
Hyperglycemia
AE 0 8 (50%) 5 (13.1%) 7 (18.9%)
SAE 0 1 (6.2%) 1 (2.6%) 2 (5.4%)
Drug-related AE 0 2 (12.5%) 2 (5.3%) 4 (10.8%)
g3-5 0 5 (31.2%) 4 (10.5%) 4 (10.8%)
Dehydration
AE 0 0 2 (5.3%) 1 (2.7%)
SAE 0 0 1 (2.6%) 0
Drug-related AE 0 0 0 1 (2.7%)
g3-5 0 0 1 (2.6%) 0
Rash
AE 1 (25%) 9 (56.2%) 24 (63.1%) 28 (75.7%)
SAE* 3 (75%) 14 (87.5%) 28 (73.7%) 25 (67.6%)
Drug-related AE 1 (25%) 8 (50%) 19 (50%) 20 (54%)
g3-5 1 (25%) 0 2 (5.26%) 2 (5.4%)
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Table 2 Summary of adverse events (Continued)
Acneiform dermatitis
AE 2 (50%) 8 (50%) 11 (28.9%) 4 (10.8%)
SAE* 3 (75%) 14 (87.5%) 28 (73.7%) 25 (67.6%)
Drug-related AE 2 (50%) 6 (37.5%) 9 (23.7%) 3 (8.1%)
g3-5 0 0 1 (2.6%) 0
Paronychia
AE 1 (25%) 1 (6.2%) 8 (21.05%) 6 (16.2%)
SAE 0 0 0 0
Drug-related AE 0 1 (6.2%) 5 (13.1%) 4 (10.8%)
g3-5 0 0 0 0
Related deaths 0 0 1 (2.6%)** 0
Treatment discontinuations*** 0 1 (6.25%) 2 (5.26%) 1 (2.7%)
N, number of patients; AE, adverse event; SAE serious adverse event; g 3-5, grade 3 to 5 according to National Cancer Institute Common Terminology Criteria for
Adverse Events.
*The information on SAE related to the skin is collected together.
**One patient presented with Interstitial Lung Disease and died despite discontinuing erlotinib.
***Includes only discontinuations due to drug-related SAEs.
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the experimental arm at the time of disease progression.
The best response for this subgroup of patients was SD
in four patients (lasting 15 months in one patient and
less than three months in three patients). At the time of
the first evaluation after crossover, six patients had pro-
gressed and no response assessment was done in four
patients. None of the patients who crossed over
harbored EGFR or KRAS mutations.
Discussion
Although the present study has confirmed the general
safety and tolerability of the combination of erlotinibTable 3 Summary of outcomes in phase II trial
Outcome Erlotinib
10
N = 38
Response
Partial response 3 (7.9%)
Complete response 0
Overall response 3 (7.9%)
Not evaluable 1 (2.6%)
Progressive disease 14 (36.8%)
Stable disease 21 (55.3%)
Stable disease ≤3 months 11 (28.9%)
Stable disease 4-12 months 7 (18.42%)
Stable disease >12 months 3 (7.9%)
Progression-free survival (months) 1.6
Overall survival (months) 10.2
HR = hazard ratio.plus dalotuzumab in patients with advanced NSCLC, no
benefit was observed in terms of efficacy. In fact, the RR
for the combination of erlotinib and dalotuzumab was
lower than the 8-10% obtained with standard therapies
in recurrent advanced NSCLC, including not only
chemotherapy but also EGFR tyrosine kinase inhibitors
(TKIs) such as gefitinib and erlotinib [10,11]. Even
though the sample size was small, the study was powered
to detect clinically significant differences in PFS.
As expected from previous dose-escalation studies,
toxicity was mild and mainly related to erlotinib [12-14].
The major concern regarding IGF1R inhibition is the
risk of hyperglycemia. In a previous trial of figitumumab,Dalotuzumab
mg/kg plus erlotinib
N = 37
Difference in rates: -0.052
(95% CI: -0.069-0.185); p = 0.317
1 (2.7%)
0
1 (2.7%)
4 (10.8%)
11 (29.7%)
21 (56.7%)
10 (27%)
7 (18.9%)
2 (5.4%)
2.5 HR, 0.86 (95% CI: 0.47-1.57); p = 0.268
6.6 HR, 1.80 (95% CI: 0.87-3.72); p = 0.946
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diabetes, and grade 3-5 hyperglycemia rates were almost
20% in both arms of the trial [15]. In our study, less than
20% of the patients in both arms had hyperglycemia
(grade 3-4 in 10% in each arm), and in all cases, it was
manageable with insulin. Although grade 3 and 4 hyper-
glycemia was recorded, it was not considered a DLT
since according to the protocol specifications the event
was controlled within the first 48 hours. Moreover,
hyperglycemia was well controlled in the current study
in patients with a previous diagnosis of diabetes mellitus
who were receiving treatment at enrollment.
The cumulative experience of using MoAbs directed
against IGF1R in combination with different therapies in
unselected NSCLC patients raises the question of why
promising evidence in the laboratory has failed repeat-
edly when translated into the clinical setting. One reason
could be the excessive toxicity of the combinations.
For example, when anti-IGF1R MoAbs were combined
with chemotherapy or erlotinib, toxicity may well have
prevented the optimum synergistic effect. Conversely,
and similar to our findings, the toxicity profile was
quite acceptable with erlotinib plus R1507 [16]. In fact,
the majority of side effects were related to erlotinib,
and the addition of the anti-IGF1R MoAb did not
significantly increase the risk of toxicity.
A second explanation for the failure of dual IGF1R
and EGFR inhibition may lie in the influence of KRAS or
EGFR mutations. Patients with KRAS mutations had a
higher 12-week PFS rate than those with wild-type KRAS
(36% vs. 0%) when treated with erlotinib plus R1507
[16]. In the present study, all five patients with KRAS
mutations had progressive disease. EGFR mutations did
not correlate with outcome to erlotinib plus R1507 [16].
In the present study, only one of the four patients with
EGFR mutations was allocated to the experimental arm.
Although this patient had stable disease lasting seven
months, it is impossible to draw any conclusions from
this individual case.
Conclusion
In conclusion, the present study has shown that although
the combination of dalotuzumab plus erlotinib is generally
tolerable, it does not confer greater benefit than erlotinib
alone in advanced NSCLC patients who are EGFR-TKI
naïve. The cumulative results of this and other studies of
dual IGF1R and EGFR inhibition indicate that further
investigation of such combinations is not warranted in
unselected NSCLC patients.
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